Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand...

Area of Science:

• Nuclear medicine
• Oncology
• Radiopharmaceutical therapy

Background:

• 177Lu]Lu-DOTA-TATE radioligand therapy (RLT) is standard for somatostatin-receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
• Effective RLT necessitates precise patient selection, monitoring, and response assessment using SSTR-targeted imaging.
• GEP-NET heterogeneity challenges standardized care guidelines and introduces conflicting data on novel monitoring approaches.

Purpose of the Study:

• To discuss emerging evidence on imaging, clinical biochemistry, and tumor assessment for RLT in GEP-NETs.
• To document best practices for monitoring and surveillance in patients undergoing RLT for GEP-NETs.
• To offer practical guidance for implementing tailored monitoring strategies in clinical decision-making.

Main Methods:

• Review of emerging evidence on imaging modalities for GEP-NETs.
• Analysis of clinical biochemistry markers relevant to RLT.
• Evaluation of tumor assessment criteria in the context of RLT.
• Documentation of institutional best practices for patient management.

Main Results:

• Discussion of current evidence regarding imaging, biochemistry, and tumor assessment in RLT for GEP-NETs.
• Presentation of institutional best practices for monitoring and surveillance.
• Highlighting the need for tailored approaches due to GEP-NET heterogeneity.

Conclusions:

• Effective management of GEP-NETs treated with RLT requires integrating diverse monitoring data.
• Emerging evidence supports refined strategies for surveillance and response assessment.
• Practical guidance is essential for optimizing patient-tailored clinical decision-making in RLT for GEP-NETs.